Suppr超能文献

墨西哥肾移植受者的皮肤癌发病率:超过 56 年的队列研究。

Skin cancer incidence in Mexican renal transplant recipients: a cohort over 56 years.

机构信息

Dermatology Department, National Institute of Nutrition Salvador Zubirán, Mexico City, Mexico.

Internal Medicine Department, National Institute of Nutrition Salvador Zubirán, Mexico City, Mexico.

出版信息

Int J Dermatol. 2024 Nov;63(11):e315-e321. doi: 10.1111/ijd.17332. Epub 2024 Jun 21.

Abstract

BACKGROUND

Skin cancer is a primary health concern in renal transplant recipients (RTRs). Existing research mainly stems from North America, Europe, and Australia, with limited data from Latin America.

METHODS

This 56-year (1967-2023) retrospective cohort study explores skin cancer incidence in Mexican RTRs. Our objective was to assess the long-term incidence of malignant cutaneous neoplasms in Mexican RTRs.

RESULTS

Over 56 years, 1642 RTRs (58% male) were studied. Median follow-up was 8.4 years; median age at transplantation was 32.6 years. Skin cancer incidence was 6.6% (95% CI: 5.5-7.9), with an incidence density rate of 6.5 (95% CI: 5.4-7.9) per 1000 person-years and a median latency of 9.8 years. Incidence increased with longer transplantation-related immunosuppression (TRI), with a relative risk for >30 years of TRI of 4.8 (95% CI: 2.6-9.1) for any skin cancer and 7.5 (95% CI: 3.8-14.6) for squamous cell carcinoma (SCC). SCC was the most common malignancy (76.1%), followed by basal cell carcinomas (BCC), with a 3.6:1 ratio. Metastatic SCC occurred in 6.5% of skin cancer patients, with a skin cancer-related mortality rate of 2.7%. Limitations of the study include its single-center and retrospective design and unassessed factors such as human papillomavirus infection and sun exposure.

CONCLUSIONS

Our study provides unique insights into the epidemiology of skin cancer among Mexican RTRs. It constitutes the largest cohort of skin cancer cases among RTRs in Mexico and, to our knowledge, in Latin America. Despite the lack of recognition of a high skin cancer incidence in non-White RTRs, our 6.6% incidence underscores the need to enhance surveillance programs.

摘要

背景

皮肤癌是肾移植受者(RTR)的主要健康关注点。现有研究主要来自北美、欧洲和澳大利亚,来自拉丁美洲的数据有限。

方法

本研究为一项 56 年(1967-2023 年)回顾性队列研究,旨在探讨墨西哥 RTR 皮肤癌的发病率。我们的目的是评估墨西哥 RTR 恶性皮肤肿瘤的长期发病率。

结果

在 56 年的时间里,研究了 1642 名 RTR(58%为男性)。中位随访时间为 8.4 年;移植时的中位年龄为 32.6 岁。皮肤癌发病率为 6.6%(95%CI:5.5-7.9),发病率密度为 6.5(95%CI:5.4-7.9)/1000 人年,潜伏期中位数为 9.8 年。发病率随移植相关免疫抑制(TRI)时间的延长而增加,TRI 超过 30 年的相对风险为任何皮肤癌的 4.8(95%CI:2.6-9.1)和鳞状细胞癌(SCC)的 7.5(95%CI:3.8-14.6)。SCC 是最常见的恶性肿瘤(76.1%),其次是基底细胞癌(BCC),比例为 3.6:1。转移性 SCC 发生在 6.5%的皮肤癌患者中,皮肤癌相关死亡率为 2.7%。研究的局限性包括其单中心和回顾性设计以及未评估的因素,如人乳头瘤病毒感染和阳光暴露。

结论

本研究提供了墨西哥 RTR 皮肤癌发病情况的独特见解。这是墨西哥也是我们所知的拉丁美洲最大的 RTR 皮肤癌病例队列。尽管非白人 RTR 皮肤癌发病率高未得到认可,但我们的 6.6%发病率强调了加强监测计划的必要性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验